PAVmed Inc (PAVM)

Currency in USD
0.464
-0.026(-5.31%)
Closed·
After Hours
0.470+0.006(+1.21%)
·
PAVM Scorecard
Full Analysis
RSI suggests the stock is in oversold territory
Trading near 52-week Low
PAVM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.4610.519
52 wk Range
0.4611.900
Key Statistics
Prev. Close
0.49
Open
0.487
Day's Range
0.461-0.519
52 wk Range
0.461-1.9
Volume
141.57K
Average Volume (3m)
160.57K
1-Year Change
-40.94%
Book Value / Share
1.11
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PAVM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.500
Upside
+2,378.45%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

PAVmed Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

PAVmed Inc Company Profile

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York

PAVmed Inc Earnings Call Summary for Q1/2025

  • PAVmed reported Q1 2025 GAAP net income of $18.6M, with positive EPS, driven by a $21M gain from Lucid Diagnostics investment
  • Company restructured debt, reducing liabilities by $25M through exchange of 80% outstanding debt for preferred equity
  • Strategic partnership with Ohio State University aims to enroll 1,000 patients in first year, with plans for 300 Verus implants post-clearance
  • CEO expects 'imminent' Medicare coverage for EsoGuard product, positioning company to accelerate commercialization efforts
  • Despite strong financials, stock dipped 1.1% in premarket trading; analyst price targets range from $4 to $19.50
Last Updated: 15/05/2025, 14:22
Read Full Transcript

Compare PAVM to Peers and Sector

Metrics to compare
PAVM
Peers
Sector
Relationship
P/E Ratio
0.1x−3.6x−0.5x
PEG Ratio
0.00−0.190.00
Price/Book
0.4x2.8x2.6x
Price / LTM Sales
4.1x2.6x3.3x
Upside (Analyst Target)
-42.5%43.5%
Fair Value Upside
Unlock6.6%6.9%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 11.500
(+2,378.45% Upside)

Earnings

Latest Release
May 15, 2025
EPS / Forecast
0.34 / --
Revenue / Forecast
8.00K / 1.40M
EPS Revisions
Last 90 days

PAVM Income Statement

People Also Watch

19.570
PST
+0.77%
16.26
SRPT
-2.93%
16.000
BMED
+1.72%
1.000
PALI
-1.96%

FAQ

What Stock Exchange Does PAVmed Trade On?

PAVmed is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for PAVmed?

The stock symbol for PAVmed is "PAVM."

What Is the PAVmed Market Cap?

As of today, PAVmed market cap is 8.18M.

What Is PAVmed's Earnings Per Share (TTM)?

The PAVmed EPS (TTM) is 6.61.

From a Technical Analysis Perspective, Is PAVM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has PAVmed Stock Split?

PAVmed has split 1 times.

How Many Employees Does PAVmed Have?

PAVmed has 39 employees.

What is the current trading status of PAVmed (PAVM)?

As of 07 Aug 2025, PAVmed (PAVM) is trading at a price of 0.46, with a previous close of 0.49. The stock has fluctuated within a day range of 0.46 to 0.52, while its 52-week range spans from 0.46 to 1.90.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.